Acromegaly is a chronic systemic disease with many complications and is associated with
increased mortality when not adequately treated. Substantial advances in acromegaly …

Somatostatin analogs are an invaluable therapeutic option in the diagnosis and treatment of
somatotropinomas, thyrotropinomas, and functioning and non-functioning …

Acromegaly is a rare disorder caused by chronic growth hormone (GH) hypersecretion.
While diagnostic and therapeutic methods have advanced, little information exists on trends …

Abstract In March 2013, the Acromegaly Consensus Group met to revise and update
guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled …

Acromegaly is a rare disease, associated with multiple organs and systems damage. Thanks
to implementation of registries, systematic data gathering, knowledge sharing and …

Context Acromegaly is a rare disease associated with chronic multisystem complications.
National registries have been created in several countries. Design The French Registry …

Introduction: Biochemical efficacy of somatostatin receptor ligand (SRL) treatment in
acromegaly is defined by metrics for GH and IGF-1 control. Since the earliest therapeutic …

Context: Acromegaly is a systemic disorder caused by a GH-secreting pituitary adenoma. As
with other rare diseases, acromegaly registries developed in various European countries …

Background Acromegaly is a rare disease with significant morbidity and increased mortality.
Epidemiological data about therapeutic outcome under 'real life'conditions are scarce …

Objective To describe the treatment and long-term outcomes of patients with acromegaly
from all healthcare regions in Sweden. Design and methods Analysis of prospectively …